Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Active, not recruiting · NCT03942653 · Registry updated 2026-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, mouth disorder, neoplasm, salivary gland cancer, salivary gland carcinoma, salivary gland disorder | Active, not recruiting | Phase 2 | 2026-07-10 | NCT03942653 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Manish Patel | 1 |
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern University Feinberg School Of Medicine | Chicago | United States | 49 |
| Univeristy of Maryland | Baltimore | United States | 1 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Iowa Hospitals and Clinics | Iowa City | United States | 99 |
| University of Michigan Health System | Ann Arbor | United States | 38 |
| University of Minnesota: Masonic Cancer Center | Minneapolis | United States | 2 |
| University of Wisconsin | Madison | United States | 64 |